DDrare: Database of Drug Development for Rare Diseases

218. アルポート症候群
［臨床試験数：16，薬物数：24（DrugBank：11），標的遺伝子数：5，標的パスウェイ数：27］

Searched query = "Alport syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = ACE I, ATA II and Statins; ACE-inhibitor; AT1-inhibitor; Atrasentan; BARDOXOLONE METHYL; Bardoxolone; Bardoxolone Methyl; Bardoxolone methyl; Benazepril; Benazepril, Valsartan and Fluvastatin; Delix; Fluvastatin; Gold; HMG-Coenzyme inhibitor (statin); Hydroxychloroquine; Lademirsen (SAR339375); Paricalcitol; RAMIPRIL; RG-012; RG012; RTA 402; Ramipril; Spironolactone; Valsartan

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00309257 (ClinicalTrials.gov)	January 2004	30/3/2006	Effects of an Intensified Treatment With ACE-I,ATA II and Statins in Alport Syndrome	Effects of an Intensified Treatment With ACE-inhibitors, Angiotensin II Receptor Antagonists and Statins in Alport Syndrome	Alport Syndrome	Drug: ACE I, ATA II and Statins;Drug: Benazepril , Valsartan and Fluvastatin	Mario Negri Institute for Pharmacological Research	NULL	Completed	15 Years	70 Years	Both	9	Phase 2	Italy
2	NCT02378805 (ClinicalTrials.gov)	July 1995	26/2/2015	European Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome	European Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome: Current and Novel Therapies	Alport Syndrome;Hereditary Kidney Disease;Pediatric Kidney Disease;Thin Basement Membrane Disease;Familial Benign Hematuria	Drug: ACE-inhibitor;Drug: AT1-inhibitor;Drug: HMG-Coenzyme inhibitor (statin);Drug: Spironolactone;Drug: Paricalcitol	University Hospital Goettingen	Society for Pediatric Nephrology (Germany);Deutsche Gesellschaft für Nephrologie;Alport Selbsthilfe e.V.;Association pour l'Information et la Recherche sur les Maladies Rénales Génétiques (AIRG);KfH Foundation Preventive Medicine	Recruiting	N/A	N/A	All	500		Germany

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT00309257
(ClinicalTrials.gov)

January 2004

30/3/2006

Effects of an Intensified Treatment With ACE-I,ATA II and Statins in Alport Syndrome

Effects of an Intensified Treatment With ACE-inhibitors, Angiotensin II Receptor Antagonists and Statins in Alport Syndrome

Alport Syndrome

Drug: ACE I, ATA II and Statins;Drug: Benazepril , Valsartan and Fluvastatin

Mario Negri Institute for Pharmacological Research

NULL

Completed

15 Years

70 Years

Both

Phase 2

Italy

NCT02378805
(ClinicalTrials.gov)

July 1995

26/2/2015

European Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome

European Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome: Current and Novel Therapies

Alport Syndrome;Hereditary Kidney Disease;Pediatric Kidney Disease;Thin Basement Membrane Disease;Familial Benign Hematuria

Drug: ACE-inhibitor;Drug: AT1-inhibitor;Drug: HMG-Coenzyme inhibitor (statin);Drug: Spironolactone;Drug: Paricalcitol

University Hospital Goettingen

Society for Pediatric Nephrology (Germany);Deutsche Gesellschaft für Nephrologie;Alport Selbsthilfe e.V.;Association pour l'Information et la Recherche sur les Maladies Rénales Génétiques (AIRG);KfH Foundation Preventive Medicine

Recruiting

N/A

All

500

Germany